Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Group IIA secreted phospholipase A2 controls skin carcinogenesis and psoriasis by shaping the gut microbiota
Yoshimi Miki, … , Makoto Arita, Makoto Murakami
Yoshimi Miki, … , Makoto Arita, Makoto Murakami
Published January 25, 2022
Citation Information: JCI Insight. 2022;7(2):e152611. https://doi.org/10.1172/jci.insight.152611.
View: Text | PDF
Research Article Inflammation Microbiology

Group IIA secreted phospholipase A2 controls skin carcinogenesis and psoriasis by shaping the gut microbiota

  • Text
  • PDF
Abstract

Besides promoting inflammation by mobilizing lipid mediators, group IIA secreted phospholipase A2 (sPLA2-IIA) prevents bacterial infection by degrading bacterial membranes. Here, we show that, despite the restricted intestinal expression of sPLA2-IIA in BALB/c mice, its genetic deletion leads to amelioration of cancer and exacerbation of psoriasis in distal skin. Intestinal expression of sPLA2-IIA is reduced after treatment with antibiotics or under germ-free conditions, suggesting its upregulation by gut microbiota. Metagenome, transcriptome, and metabolome analyses have revealed that sPLA2-IIA deficiency alters the gut microbiota, accompanied by notable changes in the intestinal expression of genes related to immunity and metabolism, as well as in the levels of various blood metabolites and fecal bacterial lipids, suggesting that sPLA2-IIA contributes to shaping of the gut microbiota. The skin phenotypes in Pla2g2a–/– mice are lost (a) when they are cohoused with littermate WT mice, resulting in the mixing of the microbiota between the genotypes, or (b) when they are housed in a more stringent pathogen-free facility, where Pla2g2a expression in WT mice is low and the gut microbial compositions in both genotypes are nearly identical. Thus, our results highlight a potentially new aspect of sPLA2-IIA as a modulator of gut microbiota, perturbation of which affects distal skin responses.

Authors

Yoshimi Miki, Yoshitaka Taketomi, Yuh Kidoguchi, Kei Yamamoto, Kazuaki Muramatsu, Yasumasa Nishito, Jonguk Park, Koji Hosomi, Kenji Mizuguchi, Jun Kunisawa, Tomoyoshi Soga, Eric Boilard, Siddabasave Gowda B. Gowda, Kazutaka Ikeda, Makoto Arita, Makoto Murakami

×

Figure 5

Metabolome analysis of hydrophilic metabolites in serum.

Options: View larger image (or click on image) Download as PowerPoint
Metabolome analysis of hydrophilic metabolites in serum.
(A) Relative ab...
(A) Relative abundance of various metabolites in the serum of Pla2g2a–/– mice relative to Pla2g2a+/+ mice (n = 5). These metabolites are classified into those related to the urea cycle, ROS, choline metabolism, bacterial metabolites, others, and oncometabolites in the TCA cycle. (B) Quantification of metabolites in the urea cycle from A. The metabolic pathway in the urea cycle is illustrated. (C) Quantification of metabolites in choline metabolism from A. (D) Quantification of bacteria-specific metabolites from A. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01; Student t test. Data are compiled from 2 experiments.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts